This news release was originally published by UICC on 20 May 2022. IFPMA and many of its member companies are partners of ATOM Coalition. The ATOM Coalition brings together the most experienced organisations to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries, and to help countries develop the capacity for...
Read moreSwift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility are among the biopharmaceutical industry’s 10 lessons learned in the process of successfully developing COVID-19 vaccines and treatments. These lessons must be preserved for future ability to fight against unknown diseases. The most important lesson of the report is that we must redouble...
Read moreThis report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic.
Read more
As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient.
Read more
The COVID-19 pandemic has taught us a lot and yet we can still keep learning. While the pandemic has impacted everyone, it has provided a spark for further exploration into how clinical trials should be improved globally.
Read moreThis report highlights a select few collaborations with IFPMA companies, and details the innovative methods in which these collaborations are working to meet urgent global supply needs.
Read more
A number of global health stakeholders are asserting that the supply of COVID-19 therapeutics is a challenge globally, and that industry is largely responsible for this.
Read moreOn 3 May, 2022, the World Trade Organization (WTO) Director-General shared the outcome document that emerged from the informal process conducted with the Quad (the European Union, India, South Africa and the United States) for an intellectual property response to COVID-19 with the broader membership. WTO Member States are now expected to further discuss it...
Read moreThe Rapid Innovation Response to COVID-19 and the Role of Intellectual Property
Read more
This brochure outlines its main objectives and pillars of work. If you are interested in joining HYPER or learning more, please contact Luca Deplano, Associate Manager, Innovation Policy.
Read more
Vaccines are one of the most effective and cost-efficient medical technologies ever developed. Except for clean water, nothing has had a larger effect on global health than vaccines, especially for children.
Read moreOn World Intellectual Property (IP) Day, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Intellectual Property Organization (WIPO) co-organized an event on ‘Innovating for Better Health: Supporting Young Innovators Through IP’, celebrating the young people who are innovating to shape health progress across the world, and particularly in Africa.
Read more